Catalog No.
DHJ24002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-lambda
Clonality
Monoclonal
Target
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Concentration
3.16 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8NBP7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG 145, Anti-PCSK9, CAS: 1256937-27-5
Clone ID
Evolocumab
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, PMID: 28304224
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia, PMID: 32865373
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor, PMID: 29353350
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia, PMID: 31648705
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS), PMID: 31479722
Evolocumab: Considerations for the Management of Hyperlipidemia, PMID: 29511875
Effect of Evolocumab on Coronary Plaque Composition, PMID: 30336824
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, PMID: 28927706
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial, PMID: 27846344
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study, PMID: 32234462
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, PMID: 28859947
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia, PMID: 24678979
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), PMID: 29133605
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, PMID: 25773607
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab, PMID: 27231792
Evolocumab, PMID: 29999810
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia, PMID: 32057369
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization, PMID: 33197560
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial, PMID: 31116355
Cognition After Lowering LDL-Cholesterol With Evolocumab, PMID: 32381158
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial, PMID: 27039291
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial, PMID: 31196453
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia, PMID: 28971955
Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial, PMID: 32718248
Evolocumab in Children with Heterozygous Familial Hypercholesterolemia, PMID: 32997915
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial, PMID: 24825642
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER, PMID: 29626068
Cognitive Function in a Randomized Trial of Evolocumab, PMID: 28813214
Evolocumab: A Review in Hyperlipidemia, PMID: 26643308
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial, PMID: 32347885
Evolocumab reduces LDL-cholesterol levels in FH, PMID: 32913308
Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome, PMID: 31495548
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics, PMID: 31841795
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis, PMID: 32312223
Effects of Evolocumab on Cardiovascular Events, PMID: 28925859
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial, PMID: 31707849
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial, PMID: 32785614
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial, PMID: 26946077
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia, PMID: 31973581
Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review, PMID: 30014724
Evolocumab: First Global Approval, PMID: 26323342
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia, PMID: 30464416
The efficacy of evolocumab in the management of hyperlipidemia: a systematic review, PMID: 28488460
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients, PMID: 31686828
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial, PMID: 25282520
A safety evaluation of evolocumab, PMID: 28988500
Cost-effectiveness of Evolocumab, PMID: 30509368
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, PMID: 25282519
[Evolocumab and PROFICIO Project: Initial Results], PMID: 26652783
Profile of evolocumab and its potential in the treatment of hyperlipidemia, PMID: 26109850
For research use only. Not for human or drug use.
